Mirum charts positive course for hepatitis delta drug on first Phase III win
Mirum Pharmaceuticals has secured a positive outcome for the first late-stage trial on its chronic hepatitis delta virus (HDV) therapy,…
News
EMA approves Oryzon’s application for Phase II HOPE-2 study
Patient enrolment concludes in Vasomune’s Phase IIa Pegevongitide trial
Kodiak’s stock rallies on Phase III wAMD success
IMS26: Key readouts rock the multiple myeloma field amid shifting landscape
Akeso begins Phase III study of cadonilimab for gastric cancer
Innovent expands Phase III MarsLight-11 trial to non-squamous NSCLC
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss
